PDCD1 and neoplasm: For instance, treatment of a mouse model of non-small cell lung cancer (NSCLC) with MRX34 increased tumor infiltration of cytotoxic (CD8+) T cells and decreased CD8+PD1+ T cells while downregulating PD-L1.